Table 3

Second malignancies in young HCL patients after cladribine treatment

PatientSecond cancerHCL therapy before cladribineAge (y) at diagnosis of second cancerTime (mo) from diagnosis of HCL to second cancerTime (mo) from cladribine to second cancerSurvival (mo) from diagnosis of HCLSurvival (mo) after diagnosis of second cancerStatus
1Adenocarcinoma, colonSplenectomy531781284106Alive
2Adenocarcinoma, prostateSplenectomy, interferon, chlorambucil6431412238571Dead
2Adenocarcinoma, colonSplenectomy, interferon, chlorambucil6128189385104Dead
2Adenocarcinoma, pancreasSplenectomy, interferon, chlorambucil6937518338511Dead
3Non-Hodgkin lymphomaIFN, G-CSF6530123633737Alive
4Metastatic renal cell carcinomaSplenectomy, IFN, chlorambucil, prednisone593532063541Dead
5CMLNone49163136277115Alive
5Non-Hodgkin lymphoma (follicular)None5422319627755Alive
6Adenocarcinoma, prostateNone582432392441Alive
7Acute myeloid leukemia – FAB M2IFN, prednisone60327633347Dead
8Acute myeloid leukemiaSplenectomy, chlorambucil613952474027Dead
  • CML, chronic myelogenous leukemia; G-CSF, granulocyte colony-stimulating factor; IFN, interferon.